Juvederm vs Restylane: What the FDA Labels Actually Say

There is no single product called Juvederm and no single product called Restylane. Each name covers a line of separate FDA approved devices, and the FDA approves each one for named areas rather than for a brand. Juvederm Ultra XC, Juvederm Vollure XC and Juvederm Voluma XC carry different approvals from one another. So do Restylane Lyft, Restylane Kysse and Restylane Defyne.

That is why a head to head answer at the brand level cannot exist. Restylane Kysse is approved for lip augmentation and the correction of upper perioral lines. Juvederm Voluma XC is approved for deep injection for cheek augmentation to correct age related midface volume deficit. Those two products cannot be compared, because they were never approved to do the same thing.

Both families are hyaluronic acid gels, a sugar the body already produces, chemically cross linked so it resists breakdown and holds a shape. Both are FDA approved only in adults 22 years of age or older. Both are injected, not implanted surgically, and both are metabolized over time, which is why the FDA states plainly that patients may need to repeat the procedure to maintain the effect.

So read the rest of this page as a comparison of products, not logos. The table in the next section sets out what each named gel is actually approved to do and what its own clinical study reported about how long it held.

Every row below is taken from the manufacturer directions for use or patient information labeling filed with the FDA for that product. Read the duration column carefully, because the figures are not comparable across manufacturers. Each one comes from a different study with a different rating scale, a different definition of a responder, and a different follow up window.

One detail patients rarely hear: touch up treatments were built into several of these studies. In the Juvederm Voluma XC cheek study, 82 percent of subjects received a touch up one month after the initial treatment in order to reach the desired result, and in the Vollure XC study 51 percent did. The advertised duration assumes that second appointment happened.

Note also how narrow the approvals are. Areas you will see promoted constantly, including the jawline, the tear trough, the nose and the temples for most products, sit outside the approvals listed here. Off label use of an approved device is legal and routine in aesthetics, but it means no regulator reviewed a duration or safety claim for that area.

The technology names you hear at a consultation describe manufacturing processes, and only one of them appears in the FDA documents at all. Allergan uses Vycross across several Juvederm products, and the patient information labeling filed with the FDA for Voluma XC and Vollure XC defines it as a manufacturing process that provides a high concentration of cross linked hyaluronic acid and creates a smooth consistency gel that flows easily into the skin.

The older Juvederm products, including Ultra XC, predate that process and are often described in the trade press under the name Hylacross. That name does not appear in the FDA hosted directions for use for Juvederm Ultra XC, which describes the product only as cross linked hyaluronic acid at 24 mg/mL with lidocaine. If someone quotes you a Hylacross claim, they are quoting marketing, not labeling.

Galderma builds the Restylane line on two platforms that published work names as NASHA, meaning non animal stabilized hyaluronic acid, and Optimal Balance Technology, the second of which appears in peer reviewed literature under the trade name XpresHAn and covers Restylane Refyne and Restylane Defyne. A review of the line describes the two platforms as producing gels ranging from very firm to very flexible, with different particle sizes and different viscoelastic behavior for different regions of the face. Neither platform name appears in the FDA filed directions for use for Lyft, Kysse or Defyne, which describe those products by concentration and cross linker instead.

The practical translation is simple. Firmer, more elastic gels resist deformation and are chosen where the job is to project a structure against bone. Softer, more flexible gels move with tissue and are chosen where the area animates, such as the lips and the folds around the mouth. That is a property of the individual gel, not of the brand printed on the box, and both families make products at both ends of the range.

Every product in the table above is a hyaluronic acid gel, which means every one of them can be broken down with hyaluronidase. That is the single most important thing these two families have in common, and it is a genuine safety advantage over permanent and semi permanent fillers.

Here is the part that is rarely said out loud. The hyaluronidase products approved in the United States are not approved for dissolving filler. The prescribing information for the recombinant human hyaluronidase approved in the United States lists it as an adjuvant for subcutaneous fluid administration, for increasing the dispersion and absorption of other injected drugs, and for subcutaneous urography. Dissolving a dermal filler appears nowhere in its indications. Injectors use it for that purpose off label, guided by professional society guidance rather than by a product label.

The directions for use for both families point to the same guidance. The Juvederm and Restylane documents both instruct that if blanching appears during injection, which can indicate a blocked vessel, the injector should stop and treat in accordance with American Society for Dermatologic Surgery guidelines, which include hyaluronidase injection.

That is why the question you should ask is not whether the product is reversible. It is whether the person injecting you keeps hyaluronidase on site, has used it, and can describe what they would do in the first hour if a vessel were compromised. The FDA names unintentional injection into a blood vessel as the most concerning risk of dermal fillers and states that the resulting complications can be serious and may be permanent.

The duration figures in the table were produced by different studies and cannot be stacked against each other. A Juvederm Vollure XC result of 18 months in 59 percent of subjects and a Restylane Kysse result of 60 percent of subjects at Week 48 sound like the same kind of claim. They are not. One measured nasolabial folds on a wrinkle severity scale, the other measured lip fullness on a lip fullness scale, and folds and lips do not behave alike in any product.

Area is the strongest driver of how long a filler holds, and it has nothing to do with the brand. A gel placed deep on bone in the midface sits in a low movement, low pressure environment. The same volume in the lips is compressed, stretched and warmed thousands of times a day. That is why the midface figures in the table run in years and the lip figures run in months, across both families.

Volume matters too, and it is where real world results diverge most from study results. The study durations above were produced with a protocol that allowed a touch up at one month, and most subjects took it. A single conservative syringe placed once will not reproduce a study result that was built on optimal correction.

So when you compare quotes, compare the plan rather than the product name. Ask which gel, how many syringes, in which anatomic area, whether a touch up is anticipated and what it costs, and when the practice expects you back. Our per area cost guides set out what actually drives the quote for each region.

The variable that decides your outcome is the person holding the syringe, not the logo on it. Both families are cross linked hyaluronic acid gels. Both dissolve with the same enzyme. Both sit in the tissue plane where they were placed. Everything that distinguishes a result you like from one you do not, including plane, volume, vector, symmetry and restraint, is decided at the appointment.

The FDA frames it the same way. Its guidance to patients is to select a health care provider who is trained to perform the procedure, and its guidance to practitioners is not to inject dermal fillers without appropriate training or experience. There is no product in either family that compensates for placement in the wrong plane, and no product in either family that becomes safe in a vessel.

Watch for a specific tell at the consultation. An injector reasoning from anatomy will name the structure they want to support, the plane they will work in, the product property that suits it, and the areas they would not treat. An injector reasoning from inventory will name a brand first and fit your face to it. Ask what they would use if you could only treat one thing, and why that gel in that spot.

Two more questions do real work. Ask who performs your good faith exam and who provides medical oversight at that location, because rules on who may inject and how directly a physician must supervise vary by state. Then ask how often they treat the specific area you care about, since injecting lips well and injecting a midface well are different skills.

Ask for the product name in full. Not Juvederm, and not Restylane, but Juvederm Voluma XC or Restylane Defyne. The full name is the only thing that tells you which approval, which study and which gel property you are getting, and a practice that will not say it is worth leaving.

Ask whether the planned area is within that product's approval or outside it. Neither answer is disqualifying, because off label use is routine in aesthetics, but you are entitled to know which one you are agreeing to and why that product was chosen for that area.

Ask what happens if you dislike the result. Because both families are hyaluronic acid, the honest answer includes dissolving. Ask whether hyaluronidase is stocked on site, what the practice charges to dissolve, and how long they want you to wait before deciding. A practice with a clear policy has been through it.

Finally, ask for the plan across time rather than the price of today. How many syringes now, whether a touch up is expected at one month, what the whole correction costs, and when they expect you back. That is the number you are actually comparing between two practices, and it is rarely the number on the promotion.